Business
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato’s drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. “We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product launches, Lou is a valuable addition to the Incannex team,” said Joel Latham, Incannex’s President and Chief Executive Officer. “Lou’s deep expertise in leading clinical development across CNS and neurodegenerative disorders, coupled with experience in the synthetic cannabinoid therapeutics will be instrumental in driving the success of our global development programs.” With more than 25 years of experience in clinical development, regulatory strategy, and global medical affairs, Dr. Barbato brings significant drug development expertise in psychiatric and neurological disorders, having contributed to the successful approval and launches of multiple therapeutics, including Marplan® (treatment-resistant depression), Luvox® CR (anxiety, OCD), Marinol® (synthetic cannabinoid appetite stimulant, chemotherapy-induced nausea and vomiting) and Gilenya® (multiple sclerosis). Dr. Barbato joins Incannex from Jazz Pharmaceuticals, where he served as Global Medical Lead for several clinical-stage therapeutic programs addressing neurological disorders. At Jazz, he led cross-functional teams, with responsibility for global medical strategies working with the FDA, EMA, and PMDA. Prior to joining Jazz, Dr. Barbato served as Global Senior Medical Director at AbbVie, and, prior to AbbVie, held leadership roles at Biogen Idec, Novartis, Stiefel Laboratories (GSK), Forest Research Institute, and Solvay Pharmaceuticals, where he contributed to successful U...